This past week the FDA for the first time approved use of a gene editing-based therapy. The new treatment is for people with Sickle Cell Disease. Gene editing has the potential to transform so many areas of medicine. ChristianaCare's Gene Editing Institute is the only institute of its kind in the nation at a community-based health system, which has led GEI to take a unique approach to gene editing research.

On this week's episode, we talk with Eric Kmiec, Ph.D., Executive Director and Chief Scientific Officer at ChristianaCare's Gene Editing Institute, about the patient-centered approach his researchers take. We find out what factors the team considers first when determining what to study and learn what that means for the development of new medicines to treat cancer and inherited diseases.

Join us for a great conversation on the past, present and future of gene editing - what is working, what is not, what opportunities there are beyond medicine and so much more.

Eric Kmiec, Ph.D., is executive director and chief scientific officer at ChristianaCare's Gene Editing Institute. He is also co-founder and chief scientific officer of CorriXR Therapeutics. Widely recognized for his pioneering work in the fields of molecular medicine and gene editing, Dr. Kmiec has developed CRISPR based genetic therapies for Sickle Cell Disease and Non-Small Cell Lung Cancer. He is also Editor-in-Chief of the journal, Gene and Genome Editing.

 Links

•  ChristianaCare's Gene Editing Institute
• ChristianaCare’s Helen F. Graham Cancer Center & Research Institute
• Simple Explainer: What is CRISPR? (video)
• Eric Kmiec's Google Scholar page
• Gene Editing Institute CRISPR in the Classroom: The Gene Editing Revolution (video)

Thanks for listening and subscribing! Follow us on Facebook, Instagram, Twitter and LinkedIn.